BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a genomics company committed to transforming cancer care, today announced that it has expanded its immunohistochemistry (IHC) test offerings to ...

Caris Life Sciences aims to standardize MET immunohistochemistry testing for non-squamous non-small cell lung cancer to enhance molecular insights and treatment personalization. MET protein expression ...

On May 21, Guardant Health, Inc. (NASDAQ:GH) announced adding a full suite of immunohistochemistry to its portfolio of tumor molecular profiling tests. This addition will help oncologists identify the ...

BOSTON--(BUSINESS WIRE)--Boston Cell Standards, a company standardizing tumor tissue testing with the first immunohistochemistry laboratory reference standards, announced the publication of a journal ...

Recurrent/metastatic EC has a poor long-term prognosis, and treatment options are limited beyond first line, said Pothuri.

Background: Biomarker testing is essential for guiding first-line treatment decisions in metastatic non–small cell lung cancer (mNSCLC). Despite guideline recommendations, real-world testing patterns ...

New RNA-based algorithm is now available with the xR assay “This program is truly the intersection of all three of our business units – genomics, AI applications, and data – leveraging our deep ...

Throughout this timeframe, technological developments spawning next-generation sequencing were leading to dramatic decreases in costs and turnaround times. Alternative business models among new ...

Collaboration to produce a machine learning (ML)-based tool that automatically analyzes images of HER2 immunohistochemistry (IHC)-stained tissue slides and reports metrics that can be used to monitor ...

Pediatric Precision Medicine at the National Cancer Center Japan: Prospective Genomic Study of Pediatric Patients with Cancer as Part of the TOP-GEAR Project HER2 status was evaluated using ...